FDA: Revised dosing schedule for Bexsero approved

FDA has approved a revised dosing schedule for Bexsero (meningococcal group B vaccine). It is approved for use in individuals aged 10 through 25 years. Rather than administering 2 doses at least 1 month apart, the prescribing information has been updated to include the option of a 2-dose schedule at 0 and 6 months and a 3-dose schedule at 0, 1-2, and 6 months. The choice of dosing schedule may depend on the risk of exposure and the individual’s susceptibility to meningococcal serogroup B disease. The new dosing schedule will be discussed at the ACIP meeting in October 2024.